Latest podcast list

Tamiflu - the US press conference

Tamiflu (oseltamivir) is a neuraminidase inhibitor, developed by Roche, for the treatment of seasonal and pandemic influenza. Yet for the first time a comprehensive review of the data, by independent researchers, has shown that the claims for Tamiflu’s effectiveness have been overestimated, and that harms have been underreported.

For the full history, including the latest articles and an interactive timeline visit bmj.com/tamiflu

Here is the audio of a recent press conference where researchers and the BMJ's editors describe the findings of that research, and the systematic regulatory failures those findings expose.

    Taking part were:
  • Fiona Godlee - The BMJ editor in chief
  • Carl Heneghan - Director of Oxford University's Centre for Evidence Based Medicine
  • Peter Doshi - Assistant Professor of Pharmaceutical Health Services Research
  • Elizabeth Loder - The BMJ clinical epidemiology editor
  • David Tovey - Editor in chief, Cochrane Library
  • Ben Goldacre - Founder of the AllTrials campaign

10/04/2014 02:10

Triptans for the acute treatment of migraine

Mabel Chew, The BMJ's practice editor, talks to Tamara Pringsheim, a neurologist from the University of Calgary, about the use of triptans for acute treatment of migraine.

Read the full article:

Triptans for symptomatic treatment of migraine headache

07/04/2014 20:31

Video archive

A BMJ for India

01/02/2013 18:41

Phantom vibrations

15/12/2010 00:00

Henri IV

15/12/2010 00:00

Sleep well

24/11/2010 00:00

HIV shoots up

03/06/2010 00:00

WHO disclosure

03/06/2010 00:00